CORRECTING and REPLACING BASE10 and DNA Link COVID-19 Antibody Test Yields Promising Results
02 September 2020 - 08:34PM
Business Wire
DNA Link’s Serology Test Showed High Degree of Sensitivity
and Specificity for Detecting COVID-19 IgG Antibodies
Please replace the release with the following corrected version
due to multiple revisions.
The updated release reads:
BASE10 AND DNA LINK COVID-19 ANTIBODY TEST YIELDS PROMISING
RESULTS
DNA Link’s Serology Test Showed High Degree of Sensitivity
and Specificity for Detecting COVID-19 IgG Antibodies
BASE10 Genetics, Inc. (BASE10) announced the results of an
independent study that showed 95% sensitivity and 100% specificity
for SARS-Co-V-2 IgG antibodies using AccuFind© COVID19 IgG test by
DNA Link, Inc. The study was performed at John Hopkins
University.
BASE10 offers a COVID-19 Tracking and Recovery Program that
assists employers in launching testing and monitoring strategies
for COVID-19. The company has been working to incorporate antibody
testing to track the full life cycle of SAR-Co-V-2.
“Having a reliable COVID-19 antibody test solution is important
to our clients in understanding how the virus has affected their
specific population. Our team and DNA Link have worked hard these
past months to reach this important milestone,” says Dr. Michael
Fang, BASE10 CEO.
The two companies now plan additional studies with a selected
number of BASE10 clients to further meet regulatory compliance and
improve clinical usability. “We want to work very closely with
regulatory bodies in everything we do, while making sure good tests
are available to patients and their providers at the right place
and time,” says Elizabeth Freund, BASE10’s VP of Innovation.
“Solid science is a valuable commodity in these times of
uncertainty, and we are committed to provide the scientific rigor
of AccuFind COVID19 IgG to the world,” says Dr. Jong-Eun Lee, CEO
of DNA Link. “We look forward to continuing to gain traction with
BASE10 on this important mission.”
_____________________
About BASE10 Genetics, Inc.
BASE10 is a precision medicine company based in Chicago.
BASE10’s proprietary platform identifies precision diagnostics
technologies with high potential for improving health outcomes, and
creates turnkey disease management solutions to be deployed at
scale for insurance payors.
Media inquiries: media@base10genetics.com
About DNA Link, Inc.
Established in 2000, DNA Link is a genomics company based in
Korea. The company produces high-quality genomic data through
up-to-date technologies, discovers biomarkers for molecular
diagnostics and precision medicine. DNA Link strives to lead
personalized medicine and new drug target identification.
Media inquiries: ikjun.choi1@gmail.com +82-10-6291-6180
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200902005702/en/
Ikjun Choi ikjun.choi1@gmail.com +82-10-6291-6180